The Food and Drug Administration (FDA) has issued a nationwide recall of certain lots of dabigatran etexilate capsules, commonly known by the brand name Pradaxa, due to failed impurity and degradation tests. The affected medication was distributed in blister packs, which were packaged in cartons.
How to Tell if Your Medication is Affected
The recall includes 75-milligram and 150-milligram dabigatran etexilate capsules. To determine if your medication is affected, check the lot number and expiration date on your packaging. The affected lots are:
- Dabigatran etexilate capsules, 150 mg, 60-count blister pack: Lot number: 25141583, Expiration date: April 30, 2027
- Dabigatran etexilate capsules, 75 mg, 60-count blister pack: Lot number: 25141585, Expiration date: April 30, 2027
- Dabigatran etexilate capsules, 75 mg, 30-count blister pack: Lot number: 25141586, Expiration date: April 30, 2027
If you discover that your capsules are affected by the recall, do not stop taking your prescription medication unless instructed to do so by your pharmacist or healthcare provider. Suddenly discontinuing your medication can cause ill effects.
Original reporting: 40/29 / KHBS (NW Arkansas) — read the source article.
